Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive after welcoming positive clinical responses to a new gel formulation of its R327® drug candidate, covered by the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). Anecdotal results from two patient case studies are a positive indicator of the gel formulation’s therapeutic potential, while results from an ex vivo burn wound study indicate the R327 gel had the greatest overall efficacy against a strand of antibiotic-resistant bacteria. Recce is now advancing clinical trial applications to evaluate the R327 gel’s efficacy in common and complicated skin and soft tissue infections in the lab.

Read the full article here:  https://www.proactiveinvestors.com.au/companies/news/1023117/recce-pharmaceuticals-provides-new-hope-in-fight-against-superbugs-1023117.html

Video Interview - Recce Pharmaceuticals provides new hope in fight against superbugs